Status:
WITHDRAWN
Music Therapy For The Treatment Of Cisplatin Induced Tinnitus In Patients With rGCC: A Pilot Study
Lead Sponsor:
Indiana University
Conditions:
Relapsed Germ Cell Cancer
Cisplatin Induced Tinnitus
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Pilot study evaluating the feasibility of recruitment, retention, and compliance to a modified Heidelberg Model of Neuro-Music Therapy (mHNMT) in patients with Cisplatin-induced Tinnitus and relapsed ...
Detailed Description
This is a prospective, interventional pilot study that plans to enroll 15 patients who are receiving salvage high dose chemo and bone marrow transplant for relapsed Germ cell Cancer (rGCC). Patients w...
Eligibility Criteria
Inclusion
- ≥ 18 years old at the time of informed consent.
- English speaking.
- Ability to provide written informed consent and HIPAA authorization
- Confirmed diagnosis of CIT via a score on the TFI of 26 or greater.
- Personal history of rGCC.
- Previous exposure to cisplatin.
- Admitted to BMT service to undergo HDC-tBMR for the first time. (Because this is a feasibility study, a minimum number of MT sessions will not be required).
- Agrees not to receive music therapy outside of study.
Exclusion
- Severe hearing impairment greater than 60 dB HL in the region of the center tinnitus frequency
- Patient's tinnitus can not be pitch matched.
- Clinical diagnosis of severe mental disorder or psychiatric or neurological disease such as psychosis, epilepsy, Parkinson's disease, dementia, alcohol or drug abuse.
Key Trial Info
Start Date :
September 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2024
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04402593
Start Date
September 1 2023
End Date
December 31 2024
Last Update
June 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Indiana University Melvin & Bren Simon Cancer Center
Indianapolis, Indiana, United States, 46202